Eileen JenningsBrown - Exscientia Chief Officer
| EXAIDelisted Stock | USD 4.84 0.00 0.00% |
Insider
Eileen JenningsBrown is Chief Officer of Exscientia Ltd ADR
| Phone | 44 18 6581 8941 |
| Web | https://www.exscientia.ai |
Exscientia Management Efficiency
The company has return on total asset (ROA) of (0.2122) % which means that it has lost $0.2122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4643) %, meaning that it created substantial loss on money invested by shareholders. Exscientia's management efficiency ratios could be used to measure how well Exscientia manages its routine affairs as well as how well it operates its assets and liabilities.Exscientia Ltd ADR currently holds 18.92 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Exscientia ADR has a current ratio of 8.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Exscientia's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Blake Borgeson | Recursion Pharmaceuticals | 43 | |
| David Pompliano | Revolution Medicines | N/A | |
| John Lewicki | Mereo BioPharma Group | 73 | |
| Jared MD | Kymera Therapeutics | 60 | |
| MA MBA | Relay Therapeutics | 48 | |
| Nello MD | Kymera Therapeutics | 46 | |
| Daohong MD | Unity Biotechnology | N/A | |
| MBA JD | Recursion Pharmaceuticals | 66 | |
| Alexis AM | Relay Therapeutics | 53 | |
| Jack Anders | Revolution Medicines | 49 | |
| ACA BA | Adaptimmune Therapeutics Plc | 54 | |
| Thomas Catinazzo | Relay Therapeutics | 49 | |
| John Vavricka | Atea Pharmaceuticals | 62 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Jenna Cohen | Blueprint Medicines Corp | N/A | |
| Filip MD | Monte Rosa Therapeutics | 51 | |
| CPA CPA | Atea Pharmaceuticals | 55 | |
| Bernard JD | Sana Biotechnology | 70 | |
| Anirvan Ghosh | Unity Biotechnology | 61 | |
| Michael Secora | Recursion Pharmaceuticals | 41 | |
| Christine Granfield | Leap Therapeutics | 57 | |
Management Performance
| Return On Equity | -0.46 | |||
| Return On Asset | -0.21 |
Exscientia ADR Leadership Team
Elected by the shareholders, the Exscientia's board of directors comprises two types of representatives: Exscientia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exscientia. The board's role is to monitor Exscientia's management team and ensure that shareholders' interests are well served. Exscientia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exscientia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Overington, Chief Officer | ||
| Eileen JenningsBrown, Chief Officer | ||
| Ben AshwellFryer, VP Fin | ||
| Parker Moss, Executive Development | ||
| Ben Taylor, Chief CFO | ||
| CBE DPHIL, CEO Founder | ||
| Nikolaus Krall, Executive Medicine | ||
| Dan Ireland, Executive Secretary | ||
| Heather Togwell, Operations Mang | ||
| Caroline Rowland, Chief Officer | ||
| Chris Thomas, VP People | ||
| Garry Pairaudeau, Chief Officer | ||
| MarieLouise MD, Interim Lead | ||
| FRSE DPHIL, CEO Founder | ||
| David Hallett, Interim Officer | ||
| Michael MD, Chief Officer | ||
| Margo Mosley, VP Operations | ||
| Richard Law, Chief Officer | ||
| Sara Sherman, Vice Relations |
Exscientia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exscientia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | |||
| Return On Asset | -0.21 | |||
| Operating Margin | (10.66) % | |||
| Current Valuation | 346.92 M | |||
| Shares Outstanding | 130.82 M | |||
| Shares Owned By Insiders | 25.90 % | |||
| Shares Owned By Institutions | 20.80 % | |||
| Number Of Shares Shorted | 2.81 M | |||
| Price To Book | 1.95 X | |||
| Price To Sales | 37.10 X |
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Exscientia Stock
If you are still planning to invest in Exscientia ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Exscientia's history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |